Peer-reviewed veterinary case report
Radiotherapy with or without temozolomide for treating dog brain
By Dolera, M et al.·Published in Veterinary and comparative oncology·2018·La Cittadina Fondazione Studi e Ricerche Veterinarie, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Frameless stereotactic radiotherapy alone and combined with temozolomide for presumed canine gliomas.
- Species:
- dog
Plain-English summary
A group of dogs with brain tumors (gliomas) were treated with either a special type of radiation therapy (stereotactic volume modulated arc radiotherapy) alone or combined with a chemotherapy drug called temozolomide. The results showed that both treatments were effective, with many dogs experiencing complete or partial responses. The median survival time for dogs receiving just radiation was about 383 days, while those getting both treatments lived around 420 days. However, there was no significant difference in survival between the two treatment groups. Overall, radiation therapy proved to be a viable option for dogs with gliomas.
People also search for: dog brain tumor treatment · canine glioma radiation therapy · temozolomide for dogs with cancer
Abstract
We evaluated stereotactic volume modulated arc radiotherapy (VMAT) for canine gliomas, alone (radiotherapy [RT]) and in combination with temozolomide (RT + TMZ), compared with palliation. Overall and disease-specific survival times were estimated. Thirty dogs were palliated, 22 dogs were treated with RT and 20 with RT + TMZ. Complete and partial responses were observed in 63.2% and 90.9% of patients in the RT and RT + TMZ arms, respectively, that were alive at 1 year. Median survival in the palliation arm was 94 days (95% conformity index [CI] 87÷101). Median survivals of the RT arm (383 days, 95% CI 276÷490) and RT+TMZ arm (420 days, 95% CI 280÷560) were not significantly different (P = .61). Positive correlation with survival was found both for the ratio between target and brain (relative) volume of the tumour of <5% (P = .013) and for a clinical presentation with normal mentation (P = .032). VMAT is feasible and effective for canine brain gliomas. Combining this therapy with TMZ did not elicit any additional improvement in survival time.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28643878/